WT1 (WILMS TUMOR 1) PEPTIDE IMMUNOTHERAPY FOR CHILDHOOD RHABDOMYOSARCOMA: A Case Report

Immunotherapy using a Wilms tumor (WT1) peptide has been undergoing clinical trials for adulthood leukemia and solid cancer with promising results. In this study, the authors used WT1 peptide vaccination to treat a 6-year-old girl with metastatic alveolar rhabdomyosarcoma. She received weekly intradermal injection with HLA-A*2404-restricted, 9-mer WT1 peptide against residual bone disease. After 3 months her bone disease disappeared, concurrent with an increase in the frequency of WT1-specific cytotoxic T lymphocytes (CTLs). A high proportion of WT1-specific CTLs with effector or effector memory phenotype were detected in peripheral blood of this patient. She is currently still on continued WT1 peptide immunotherapy in a disease-free condition for 22 months. WT1 peptide-based immunotherapy should be a promising option for high-risk rhabdomyosarcoma in childhood.

[1]  J. Hatazawa,et al.  Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. , 2008, Journal of neurosurgery.

[2]  I. Kawase,et al.  WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers , 2007, TheScientificWorldJournal.

[3]  I. Kawase,et al.  Immunohistochemical detection of WT1 protein in a variety of cancer cells , 2006, Modern Pathology.

[4]  H. Sugiyama.  Cancer immunotherapy targeting Wilms’ tumor gene WT1 product , 2005, Expert review of vaccines.

[5]  T. Kyo,et al.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  I. Kawase,et al.  WT1 Peptide‐Based Immunotherapy for Patients with Lung Cancer: Report of Two Cases , 2004, Microbiology and immunology.

[7]  I. Kawase,et al.  Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis , 2003, International journal of hematology.

[8]  I. Kawase,et al.  Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues , 2002, Cancer Immunology, Immunotherapy.

[9]  P. Sorensen,et al.  PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Y. Miyoshi,et al.  High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  K. Aozasa,et al.  Cytotoxic T-Lymphocyte Responses Elicited to Wilms' Tumor Gene WT1 Product by DNA Vaccination , 2000, Journal of Clinical Immunology.

[12]  S. Groshen,et al.  Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Y. Oji,et al.  Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth , 1999, Japanese journal of cancer research : Gann.

[14]  T. Kyo,et al.  Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. , 1996, Blood.

[15]  T. Kudoh,et al.  Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. , 1996, Blood.

[16]  E. Gehan,et al.  The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Sakamoto,et al.  Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. , 2007, International journal of hematology.

[18]  James R. Anderson,et al.  Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Jochemsen,et al.  The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? , 1998, International review of cytology.